Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor) may reduce the occurrence of major adverse cardiovascular events (MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this meta-analysis, we conducted a thorough compilation of evidence from established c...
Main Authors: | Jiajing Zhao, Xinyu Tong, Jian Peng, Chuxin Lyu, Shu Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR Press
2024-03-01
|
Series: | Reviews in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.imrpress.com/journal/RCM/25/3/10.31083/j.rcm2503094 |
Similar Items
-
НОВОСТИ С КОНГРЕССОВ ПО АТЕРОСКЛЕРОЗУ 2018
Published: (2018-09-01) -
Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
by: Stefan Toth, et al.
Published: (2020-07-01) -
An update on the measurement and management of cholesterol with specific reference to secondary prevention of cardiovascular disease (CVD)
by: Muhammed Vally, et al.
Published: (2018-03-01) -
Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
by: Andreja Rehberger Likozar, et al.
Published: (2022-12-01) -
The Therapeutic Efficacy of Danhong Injection Combined With Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
by: Jun-Bo Zou, et al.
Published: (2018-06-01)